BR112013020620A2 - análogos de ácido 4-hidroxibutírico - Google Patents
análogos de ácido 4-hidroxibutíricoInfo
- Publication number
- BR112013020620A2 BR112013020620A2 BR112013020620A BR112013020620A BR112013020620A2 BR 112013020620 A2 BR112013020620 A2 BR 112013020620A2 BR 112013020620 A BR112013020620 A BR 112013020620A BR 112013020620 A BR112013020620 A BR 112013020620A BR 112013020620 A2 BR112013020620 A2 BR 112013020620A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydroxybutyric acid
- acid analogs
- compositions
- fibromyalgia
- prodrugs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/115—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/708—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
resumo patente de invenção: "análogos de ácido 4-hidroxibutírico". esta invenção refere-se a novos derivados de ácido 4-hidroxibutírico e profármacos dos mesmos, e sais farmaceuticamente aceitáveis do precedente. esta invenção também proporciona composições farmacêuticas compreendendo um composto desta invenção e o uso de tais composições em métodos de tratamento de narcolepsia, fibromialgia, outros distúrbios ou condições que são beneficamente tratados pelo melhoramento do sono noturno, ou por administração de oxibato de sódio.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161442451P | 2011-02-14 | 2011-02-14 | |
US201161484296P | 2011-05-10 | 2011-05-10 | |
PCT/US2012/024974 WO2012112492A1 (en) | 2011-02-14 | 2012-02-14 | 4-hydroxybutyric acid deuterated analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013020620A2 true BR112013020620A2 (pt) | 2016-10-04 |
Family
ID=46672903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013020620A BR112013020620A2 (pt) | 2011-02-14 | 2012-02-14 | análogos de ácido 4-hidroxibutírico |
Country Status (10)
Country | Link |
---|---|
US (5) | US8759394B2 (pt) |
EP (1) | EP2675771B1 (pt) |
JP (2) | JP2014513046A (pt) |
KR (1) | KR101976218B1 (pt) |
CN (1) | CN103370289B (pt) |
BR (1) | BR112013020620A2 (pt) |
ES (1) | ES2804540T3 (pt) |
IL (1) | IL227754B (pt) |
MX (1) | MX355742B (pt) |
WO (1) | WO2012112492A1 (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2759251C (en) | 2009-04-23 | 2017-01-03 | Concert Pharmaceuticals, Inc. | 4-hydroxybutyric acid analogs |
CA2794171C (en) | 2010-03-24 | 2018-07-03 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
ES2804540T3 (es) | 2011-02-14 | 2021-02-08 | Concert Pharmaceuticals Inc | Análogos deuterados de ácido 4hidroxibutírico |
US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
WO2017050259A1 (en) | 2015-09-23 | 2017-03-30 | Xw Laboratories Inc. | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof |
ES2899261T3 (es) | 2015-11-19 | 2022-03-10 | Kyowa Hakko Bio Co Ltd | Cristales de una sal de un catión monovalente de ácido 3-hidroxiisovalérico y método para producir dichos cristales |
CN109476578A (zh) | 2016-06-24 | 2019-03-15 | 协和发酵生化株式会社 | 3-羟基异戊酸氨基酸盐的晶体及其制造方法 |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
WO2018176343A1 (en) | 2017-03-30 | 2018-10-04 | Xw Laboratories Inc. | Bicyclic heteroaryl derivatives and preparation and uses thereof |
CN111902139A (zh) * | 2018-03-23 | 2020-11-06 | 康塞特医药品有限公司 | 氘代的D-β-羟基丁酸的类似物及其用途 |
ES2947089T3 (es) | 2018-09-30 | 2023-08-01 | Xwpharma Ltd | Compuestos como antagonistas del receptor histamínico 3 neuronal y usos de los mismos |
KR20210094513A (ko) | 2018-11-19 | 2021-07-29 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 알코올-내성 약물 제형 |
CA3127871A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
CN115244028A (zh) | 2019-12-20 | 2022-10-25 | 凯瑞康宁生物工程有限公司 | 4-缬氨酰氧基丁酸的合成方法 |
TW202139986A (zh) * | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
KR20230011359A (ko) | 2020-06-18 | 2023-01-20 | 엑스더블유파마 리미티드 | 수용성 활성 약제 성분의 제어 방출 과립화물 |
US11357734B2 (en) | 2020-06-18 | 2022-06-14 | XWPharma Ltd. | Pharmaceutical granulations of water-soluble active pharmaceutical ingredients |
US11896573B2 (en) | 2020-07-24 | 2024-02-13 | XWPharma Ltd. | Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative |
CA3194665A1 (en) | 2020-10-05 | 2022-04-14 | Jia-Ning Xiang | Modified release compositions of a gamma-hydroxybutyric acid derivative |
TW202300139A (zh) | 2021-03-19 | 2023-01-01 | 凱瑞康寧生技股份有限公司 | γ-羟基丁酸衍生物的聯合釋放製劑的藥代動力學 |
CN113200853A (zh) * | 2021-05-19 | 2021-08-03 | 宁波窦氏化学科技有限公司 | 一种制备丁二酸二醇酯的工艺方法 |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0044801B1 (de) | 1980-07-17 | 1984-02-15 | Josef Dr. Klosa | Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel |
ZA814854B (en) * | 1980-07-17 | 1982-07-28 | J Klosa | Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts |
US4548716A (en) * | 1984-07-25 | 1985-10-22 | Lucas Boeve | Method of producing ultrapure, pyrogen-free water |
US4738985A (en) | 1986-03-19 | 1988-04-19 | The University Of Toronto Innovations Foundations | Pharmaceutical composition and treatment |
JP2727008B2 (ja) * | 1989-02-01 | 1998-03-11 | 日本酸素株式会社 | 静菌化水の製造方法 |
DE4113984C2 (de) | 1991-04-29 | 2002-05-08 | Koehler Chemie Dr Franz | Salze der 4-Hydroxy-Buttersäure |
IT1248588B (it) * | 1991-06-28 | 1995-01-19 | Gaetano Crepaldi | Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari. |
WO1995026325A2 (en) | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
US5840331A (en) | 1995-06-07 | 1998-11-24 | Arch Development Corporation | Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin |
RU2224510C2 (ru) | 1997-03-17 | 2004-02-27 | Би Ти Джи Интернэшнл Лимитед | Терапевтические композиции |
US5990162A (en) * | 1997-08-29 | 1999-11-23 | Orphan Medical, Inc. | Method for treatment of fibromyalgia and chronic fatigue syndrome |
US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
DE60019435T2 (de) * | 1999-09-14 | 2006-02-23 | Tepha, Inc., Cambridge | Therapeutische anwendung von polymere die gamma-hydroxybutyrat enthalten |
US6204245B1 (en) | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
PT1104760E (pt) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios |
EP1325014B1 (en) | 2000-09-22 | 2012-05-23 | JPI Commercial, LLC | Gamma-hydroxybutyrate compositions containing carbohydrate carriers |
AU2003280960A1 (en) | 2002-07-15 | 2004-02-02 | Alcon, Inc. | Pharmaceutical compositions for otic use |
TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
CA2624179A1 (en) | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
WO2008030382A1 (en) | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
US20090082380A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched rosuvastatin |
ES2589915T3 (es) * | 2008-10-08 | 2016-11-17 | Xgene Pharmaceutical Inc | Conjugados de GABA y métodos de utilización de los mismos |
CA2759251C (en) * | 2009-04-23 | 2017-01-03 | Concert Pharmaceuticals, Inc. | 4-hydroxybutyric acid analogs |
ES2804540T3 (es) * | 2011-02-14 | 2021-02-08 | Concert Pharmaceuticals Inc | Análogos deuterados de ácido 4hidroxibutírico |
-
2012
- 2012-02-14 ES ES12704646T patent/ES2804540T3/es active Active
- 2012-02-14 US US13/372,989 patent/US8759394B2/en active Active
- 2012-02-14 MX MX2013009368A patent/MX355742B/es active IP Right Grant
- 2012-02-14 JP JP2013553647A patent/JP2014513046A/ja active Pending
- 2012-02-14 KR KR1020137024419A patent/KR101976218B1/ko active IP Right Grant
- 2012-02-14 CN CN201280008737.7A patent/CN103370289B/zh active Active
- 2012-02-14 EP EP12704646.4A patent/EP2675771B1/en active Active
- 2012-02-14 WO PCT/US2012/024974 patent/WO2012112492A1/en active Application Filing
- 2012-02-14 BR BR112013020620A patent/BR112013020620A2/pt not_active Application Discontinuation
-
2013
- 2013-08-01 IL IL227754A patent/IL227754B/en active IP Right Grant
-
2014
- 2014-04-17 US US14/255,331 patent/US9309182B2/en active Active
-
2016
- 2016-04-11 US US15/095,545 patent/US10040748B2/en active Active
-
2017
- 2017-04-20 JP JP2017083295A patent/JP6692319B2/ja active Active
-
2018
- 2018-08-06 US US16/055,407 patent/US20190100484A1/en not_active Abandoned
-
2021
- 2021-02-01 US US17/164,391 patent/US20210403407A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2014513046A (ja) | 2014-05-29 |
US20210403407A1 (en) | 2021-12-30 |
KR20140008391A (ko) | 2014-01-21 |
MX355742B (es) | 2018-04-26 |
US8759394B2 (en) | 2014-06-24 |
EP2675771A1 (en) | 2013-12-25 |
IL227754B (en) | 2018-01-31 |
JP2017165747A (ja) | 2017-09-21 |
US20160326086A1 (en) | 2016-11-10 |
US20130012565A1 (en) | 2013-01-10 |
WO2012112492A1 (en) | 2012-08-23 |
ES2804540T3 (es) | 2021-02-08 |
US9309182B2 (en) | 2016-04-12 |
US20140343119A1 (en) | 2014-11-20 |
MX2013009368A (es) | 2013-09-26 |
US10040748B2 (en) | 2018-08-07 |
JP6692319B2 (ja) | 2020-05-13 |
KR101976218B1 (ko) | 2019-05-07 |
IL227754A0 (en) | 2013-09-30 |
CN103370289B (zh) | 2015-09-09 |
EP2675771B1 (en) | 2020-04-08 |
US20190100484A1 (en) | 2019-04-04 |
CN103370289A (zh) | 2013-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013020620A2 (pt) | análogos de ácido 4-hidroxibutírico | |
HK1167641A1 (en) | 4-hydroxybutyric acid analogs 4- | |
BR112013029240A2 (pt) | derivados deuterados do ivacaftor | |
BR112015025766A2 (pt) | derivado de nucleosídeo altamente ativo para o tratamento de hcv | |
BR112018005454A2 (pt) | administração de potencializadores de cftr deuterados | |
BR112016003348A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade efetiva de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica | |
EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
BR112014015845A2 (pt) | derivados de azetidina, composições farmacêuticas e seu uso | |
BR112014000371A2 (pt) | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença | |
BR112015012366A2 (pt) | antagonistas de cxcr7 | |
EA201500265A1 (ru) | Ингибиторы репликации вирусов гриппа | |
BR112014009528A8 (pt) | métodos e composições para tratar eritropoiese ineficaz | |
BR112015014458A2 (pt) | derivados de manose para o tratamento de infecções bacterianas | |
BRPI0807749B8 (pt) | composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos | |
BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
BR112013020042A2 (pt) | inibidores de vírus da hepatite c | |
BRPI0516454A (pt) | compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, sua utilização, método para o tratamento e profilaxia de enfermidades, e de diabetes do tipo ii | |
BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
BR112014008036A2 (pt) | tratamento de rinite | |
BR112014004963A2 (pt) | sal de colina do composto anti-inflamatório ciclobutanodiona substituído | |
BR112022021962A2 (pt) | Imidazopiridazinas como moduladores de il-17 | |
BR112014010729A2 (pt) | métodos para tratamento de ataques de gota | |
BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |